HBM BioVentures

de

Investment Guidelines

Board of Directors

Cayman Subsidiary

Investment Manager

Investment Advisor Europe

Investment Advisor USA

Corporate Governance

Articles of Association

Board of Directors of HBM BioVentures Ltd

Hans Peter Hasler (Chairman)
Prof. Dr Dr h.c. mult. Heinz Riesenhuber (Vice Chairman)
Dr Eduard E. Holdener
Robert A. Ingram
Dr Rudolf Lanz

Dr Dr h.c. Henri B. Meier (Honorary Chairman)

Dr Benedikt Suter (Secretary)

News

Press Releases
»	HBM BioVentures Quarterly Report as at 30 June 2010
»	HBM BioVentures’ largest public investment – Micrus – acquired by Johnson & Johnson
»	HBM BioVentures sells USD hedging position at a profit
»	Shareholders’ meeting approves all proposals by Board of Directors by large majority; Hans Peter Hasler appointed as new Chairman of the Board of Directors; Astellas, which recently acquired OSI Pharmaceuticals, will retain HBM BioVentures shares and intensify cooperation
»	Archive

Financial Reports

»	Quarterly Report June 2010
»	Annual Report 2009/2010
»	Archive

Share Price

SIX Swiss Exchange Ticker
HBMN

Key Figures

as at 31.8.2010	CHF

NAV per share	62.58
Net assets	616 Mio.

Search

News Registration